1
|
Rème T, Gueydon E, Jacquet C, Klein B, Brochier J. Growth and immortalization of human myeloma cells in immunodeficient severe combined immunodeficiency mice: a preclinical model. Br J Haematol 2001; 114:406-13. [PMID: 11529865 DOI: 10.1046/j.1365-2141.2001.02947.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Human multiple myeloma (MM) purified tumour cells readily undergo apoptosis in vitro. Interleukin 6 (IL-6), a main growth factor of tumour cells, has enabled the development of IL-6-dependent MM cell lines. Recently, we developed anti-gp130 monoclonal antibodies (mAbs), two of which (B1 + I2) were able to dimerize gp130 and replace IL-6 in vitro. We show here that the injection of B1 + I2 IL-6 agonistic mAbs via the inguinal subcutaneous (SC) route efficiently produced tumours in severe combined immunodeficiency (SCID) mice grafted with IL-6-dependent myeloma cell lines compared with either the intraperitoneal (IP) or abdominal surgical bursa (SB) routes. The SC tumour graft, together with Matrigel and vascular endothelial growth factor (VEGF), leads to a strong vascularization and early detection of serum human immunoglobulins (huIgs). SCID mice treated with B1 + I2 mAbs were injected with fresh MM cells from five patients, four of whom had consistent levels of huIgs, and tumour growth was present in two. For one patient, tumour plasma cells that were passed several times subcutaneously in new SCID mice, still expressed their initial markers after several months. They remained unable to grow in vitro in the presence of B1 + I2 or IL-6. The nature of the SCID factors involved and the triggered genes are under investigation.
Collapse
Affiliation(s)
- T Rème
- INSERM U475, Montpellier, France.
| | | | | | | | | |
Collapse
|
2
|
Millard I, Degrave E, Philippe M, Gala JL. Detection of intracellular antigens by flow cytometry: comparison of two chemical methods and microwave heating. Clin Chem 1998. [DOI: 10.1093/clinchem/44.11.2320] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Detection of intracellular antigens by flow cytometry requires effective fixation and permeabilization of the cell membrane. This study compares three fixation/permeabilization techniques: two commercial chemical reagents, the ORTHOPermeaFixTM (OPF) and the FIX&PERM Cell Permeabilization Kit® (F&P), and a novel method based on microwave heating (MWH). They have been applied to the detection of two nuclear (p53 and rb/p105) and two cytoplasmic (bcl-2 and mdr-1/gp-170) antigens, using positive- and negative-control cell lines and peripheral blood mononuclear cells. Western blotting was performed as a control of protein expression. For the four antigens assessed, cellular morphology, discrimination between intact cells and debris, percentage of positive cells, and mean fluorescence intensity were examined. For this last parameter, the assessment of the MWH technique was performed using SD and a graphical approach inspired by the concepts described by Bland and Altman (Lancet 1986;346:1085–7) as well as Petersen et al. (Clin Chem 1997;43:2039–46). The statistical analysis shows that MWH is comparable to the commercial methods and that its reproducibility is also equivalent to OPF and F&P. As assessed for some of the most clinically relevant intracytoplasmic and intranuclear antigens, the MWH method appears to be a valuable and inexpensive alternative. It is worth noting that, unlike commercial reagents, MWH altered surface antigens. Interestingly, this feature, which would prevent cell selection on the basis of combined membrane and intracellular epitopes, is associated with a decrease of nonspecific background fluorescence.
Collapse
Affiliation(s)
- Isabelle Millard
- Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Clinical Biochemistry Department, Clos-Chapelle-aux-Champs, 30-UCL 30.46, 1200 Brussels, Belgium
| | - Etienne Degrave
- Scientific Section of the Medical Staff, Belgium Armed Forces, Queen Astrid Military Hospital, Rue Bruyn, 2, 1120 Brussels, Belgium
| | - Marianne Philippe
- Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Clinical Biochemistry Department, Clos-Chapelle-aux-Champs, 30-UCL 30.46, 1200 Brussels, Belgium
| | - Jean-Luc Gala
- Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Clinical Biochemistry Department, Clos-Chapelle-aux-Champs, 30-UCL 30.46, 1200 Brussels, Belgium
- Scientific Section of the Medical Staff, Belgium Armed Forces, Queen Astrid Military Hospital, Rue Bruyn, 2, 1120 Brussels, Belgium
| |
Collapse
|